1. Home
  2. APAM vs IMNM Comparison

APAM vs IMNM Comparison

Compare APAM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

APAM

Artisan Partners Asset Management Inc.

HOLD

Current Price

$42.78

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$25.52

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APAM
IMNM
Founded
1994
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.5B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
APAM
IMNM
Price
$42.78
$25.52
Analyst Decision
Hold
Strong Buy
Analyst Count
5
10
Target Price
$43.00
$32.80
AVG Volume (30 Days)
922.9K
1.1M
Earning Date
04-28-2026
05-08-2026
Dividend Yield
10.81%
N/A
EPS Growth
10.66
51.40
EPS
1.90
N/A
Revenue
$1,196,688,000.00
$6,941,000.00
Revenue This Year
$5.96
N/A
Revenue Next Year
$5.05
$1,127.34
P/E Ratio
$22.47
N/A
Revenue Growth
7.63
N/A
52 Week Low
$33.96
$8.67
52 Week High
$48.46
$27.65

Technical Indicators

Market Signals
Indicator
APAM
IMNM
Relative Strength Index (RSI) 71.19 68.90
Support Level $42.64 $19.28
Resistance Level $45.21 $25.07
Average True Range (ATR) 1.17 1.08
MACD 0.32 0.15
Stochastic Oscillator 89.89 81.18

Price Performance

Historical Comparison
APAM
IMNM

About APAM Artisan Partners Asset Management Inc.

Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: